Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test

NEW YORK – Thermo Fisher Scientific said on Tuesday that it has partnered with AstraZeneca to develop a solid tissue and blood-based companion diagnostic test for the drug firm's Tagrisso (osimertinib), a non-small cell lung cancer (NSCLC) drug.

This partnership is part of a global, multiyear agreement that the companies signed in 2021 to codevelop next-generation sequencing-based companion diagnostic tests to support AstraZeneca's portfolio of targeted therapies.

For this collaboration, the companies will develop a solid tissue and blood-based CDx using Thermo Fisher Scientific's Oncomine Dx Express Test on the Genexus Dx System, a fully integrated next-generation sequencing platform capable of completing an automated specimen-to-report workflow in as little as 24 hours.

The CDx will help screen for NSCLC patients who may be eligible for Tagrisso treatment by identifying tumors that exhibit epidermal growth factor receptor (EGFR) alterations including exon 21 L858R mutations, exon 19 deletions, or T790M mutations.

“By leveraging the Genexus Dx System’s unprecedented turnaround time, we can help ensure molecular testing results are more readily available to inform vital treatment decisions,” Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher, said in a statement.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.